Immunic Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	2018 - 2012
Net Income	-97.92	-93.61	-120.41	-92.95	-44.02	-34.93	Upgrade
Depreciation & Amortization	0.11	0.11	0.08	0.09	0.04	0.05	Upgrade
Share-Based Compensation	7.87	7.1	7.93	5.95	2.75	6.51	Upgrade
Other Operating Activities	14.66	15.57	47.26	3.68	-4.89	-0.17	Upgrade
Operating Cash Flow	-75.28	-70.83	-65.14	-83.23	-46.12	-28.55	Upgrade
Capital Expenditures	-0.26	-0.33	-0.11	-0.07	-0.15	-0.02	Upgrade
Acquisitions	0	0	0	0	0	10.55	Upgrade
Change in Investments	4.36	9.8	-9.63	0	0	0	Upgrade
Investing Cash Flow	4.1	9.46	-9.74	-0.07	-0.15	10.54	Upgrade
Share Issuance / Repurchase	75.45	0.98	95.76	42.84	144.43	35.17	Upgrade
Other Financing Activities	-	0.05	-	-	-	-0.27	Upgrade
Financing Cash Flow	75.45	1.03	95.76	42.84	144.43	34.9	Upgrade
Exchange Rate Effect	0.29	0.26	-0.99	-0.13	-0.08	-0.59	Upgrade
Net Cash Flow	4.55	-60.07	19.88	-40.59	98.08	16.3	Upgrade
Free Cash Flow	-75.55	-71.16	-65.26	-83.3	-46.27	-28.56	Upgrade
Free Cash Flow Per Share	-0.78	-1.61	-2.05	-3.52	-2.95	-3.70	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).